
PolarisQB leverages quantum computing and quantum-inspired algorithms to revolutionize drug discovery. Their QuADD platform enables exploration of a vastly larger chemical space (10^30) compared to traditional screening (10^10), leading to faster identification and optimization of drug candidates. They focus on multi-object optimization at scale and speed, applicable to any protein target without requiring training data. PolarisQB offers solutions like QuADD Rapid for lead-like molecules and QuADD Select for optimized molecules ready for synthesis, significantly shortening discovery timelines from months or years to days or weeks. They serve the pharmaceutical, biotech, agriculture, and CRO industries, aiming to make drug blueprints more accessible and affordable.

PolarisQB leverages quantum computing and quantum-inspired algorithms to revolutionize drug discovery. Their QuADD platform enables exploration of a vastly larger chemical space (10^30) compared to traditional screening (10^10), leading to faster identification and optimization of drug candidates. They focus on multi-object optimization at scale and speed, applicable to any protein target without requiring training data. PolarisQB offers solutions like QuADD Rapid for lead-like molecules and QuADD Select for optimized molecules ready for synthesis, significantly shortening discovery timelines from months or years to days or weeks. They serve the pharmaceutical, biotech, agriculture, and CRO industries, aiming to make drug blueprints more accessible and affordable.
Founded: 2020
Headquarters: Durham, North Carolina, United States
Sector: Biotechnology — quantum computing + AI for drug discovery
Stage / Funding: Seed (announced Aug 10, 2021)
Founders / Leadership: Shahar Keinan (Co-founder & CEO), Bill Shipman (Co-founder & CTO)
Small-molecule drug discovery and optimization across pharmaceutical, biotech, agriculture, and CRO customers.
2020
Biotechnology
Investors listed: OurCrowd and Infinity Medical